Comparative Pharmacology
Head-to-head clinical analysis: CASPOFUNGIN ACETATE versus ERAXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CASPOFUNGIN ACETATE versus ERAXIS.
CASPOFUNGIN ACETATE vs ERAXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Caspofungin acetate is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, by noncompetitively inhibiting the enzyme 1,3-beta-D-glucan synthase. This leads to osmotic instability and cell lysis, primarily against Candida and Aspergillus species.
Echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls, by noncompetitive inhibition of the enzyme 1,3-beta-D-glucan synthase.
Adults: 70 mg IV loading dose on day 1, then 50 mg IV once daily.
50 mg intravenously once daily for invasive candidiasis; 100 mg intravenously once daily for esophageal candidiasis.
None Documented
None Documented
Terminal elimination half-life ~9-11 hours in adults, with a prolonged terminal phase (beta half-life 40-50 hours) due to slow tissue distribution and redistribution. Clinically, dosing interval is 24 hours.
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), supporting once-weekly intravenous dosing.
Primarily hepatic: slow metabolism with subsequent biliary and fecal excretion. ~35% of administered dose excreted in feces and ~41% in urine over 27 days, with <2% unchanged in urine. Minimal renal excretion as unchanged drug.
Primarily excreted unchanged in feces (~70%) and urine (~10% as unchanged drug and metabolites). Biliary excretion is the major route for unchanged drug.
Category A/B
Category C
Echinocandin Antifungal
Echinocandin Antifungal